Claims for Patent: 4,584,305

Summary for Patent: 4,584,305

Title:	Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole
Abstract:	Process of aiding regression and palliation of neoplastic disease in animal and human hosts comprising systemic administration to phenylimidazo[2,1-b]thiazole or a nontoxic acid addition salt thereof. Preferably the active ingredient is administered in a sufficient amount to provide dosages over the range from about 1 mg to about 5 mg/kg of body weight of the host.
Inventor(s):	Brugmans; Josephus (Schilde-Antwerp, BE), Pollack; William (Belle Mead, NJ), Janssen; Paul A. J. (Vosselaar, BE), Tripodi; Daniel (Westford, MA)
Assignee:	Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:	06/230,578
Patent Claims:	1. A process of aiding regression and palliation of neoplastic disease which comprises the systemic administration to human and animal subjects hosting the neoplastic disease of an effective anti-neoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydo-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 2. A process of aiding regression and palliation of neoplastic disease which comprises the systemic administration to a human hosting the neoplastic disease of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof. 3. A process of aiding regression and palliation of pulmonary metastatic tumor which comprises the systemic adminstration to a host of said tumor of an effective tumor-inhibiting amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 4. A process of aiding regression palliation of breast cancer which comprises the systemic administration to human or animal subjects hosting breast cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 5. A process of aiding regression and palliation of breast cancer which comprises the systemic administration to a human hosting breast cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof. 6. A process of aiding regression and palliation of lung cancer which comprises the systemic administration to human or animal subjects hosting lung cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 7. A process of aiding regression and palliation of lung cancer which comprises the systemic administration to a human hosting lung cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof. 8. A process of aiding regression and palliation of malignant melanoma which comprises the systemic administration to human or animal subjects hosting malignant melanoma of an effective antineoplastic amount of a member from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[1,2-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 9. A process of aiding regression and palliation of malignant melanoma which comprises the systemic administration to a human hosting malignant melanoma of from about 1 to about 5 mg/kg body weight of the host member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof. 10. A process of aiding regression and palliation of colorectal cancer which comprises the systemic administration to human or animal subject hosting colorectal cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 11. A process of aiding regression and palliation of colorectal cancer which comprises the systemic administration to a human hosting colorectal cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof. 12. A process of aiding regression and palliation of multiple myeloma which comprises the systemic administration to human or animal subjects hosting multiple myeloma of an effective antineoplastic amount of a memeber selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 13. A process of aiding regression and palliation of multiple myeloma which comprises the systemic administration to a human hosting multiple myeloma of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutcially active acid addition salts thereof. 14. A process of aiding regression and palliation of head and neck cancer which comprises the systemic administration to human or animal subjects hosting head and neck cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 15. A process of aiding regression and palliation of head and neck cancer which comprises the systemic administration to a human hosting head and neck cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof. 16. A process of aiding regression and palliation of gastric cancer which comprises the systemic administration to human and animal subjects hosting gastric cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier. 17. A process of aiding regression and palliation of gastric cancer which comprises the systemic administration to a human hosting gastric cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof.